ERBB2 and breast carcinoma: We performed a model-based economic evaluation that examined the cost-effectiveness of 5 neoadjuvant followed by adjuvant treatment strategies for ERBB2-positive breast cancer by modeling our patient population and outcomes based on the KATHERINE trial.